Theratechnologies Inc. (THTX)
- Previous Close
1.3000 - Open
1.3600 - Bid 0.9432 x 200
- Ask 1.6800 x 200
- Day's Range
1.3200 - 1.3656 - 52 Week Range
0.8800 - 4.3200 - Volume
6,657 - Avg. Volume
35,030 - Market Cap (intraday)
61.301M - Beta (5Y Monthly) 1.78
- PE Ratio (TTM)
-- - EPS (TTM)
-0.9100 - Earnings Date Jul 10, 2024 - Jul 15, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
8.67
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
www.theratech.comRecent News: THTX
Performance Overview: THTX
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: THTX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: THTX
Valuation Measures
Market Cap
60.37M
Enterprise Value
78.95M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.42
Price/Book (mrq)
--
Enterprise Value/Revenue
0.97
Enterprise Value/EBITDA
-8.01
Financial Highlights
Profitability and Income Statement
Profit Margin
-23.04%
Return on Assets (ttm)
-4.55%
Return on Equity (ttm)
--
Revenue (ttm)
78.1M
Net Income Avi to Common (ttm)
-18M
Diluted EPS (ttm)
-0.9100
Balance Sheet and Cash Flow
Total Cash (mrq)
38.45M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-1.96M